Patterns of use of thienopyridine therapy after percutaneous coronary interventions with drug-eluting stents and bare-metal stents

American Heart Journal

Volumn 158, Issue 4, 2009, Pages

  Ko, Dennis T ^a,b   Chiu, Maria ^b   Guo, Helen ^b   Austin, Peter C ^b   Marquis, Jean François ^c   Tu, Jack V ^a,b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; TICLOPIDINE;

AGED; ARTICLE; BARE METAL STENT; CANADA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DEATH; DRUG ELUTING STENT; DRUG USE; DRUG WITHDRAWAL; FEMALE; HEART FAILURE; HEMODIALYSIS; HUMAN; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEOPLASM; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; TREATMENT REFUSAL;

EID: 70349427002     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2009.06.030     Document Type: Article

References (24)

1. Moses J.W., Leon M.B., Popma J.J., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
2. Daemen J., and Serruys P.W. Drug-eluting stent update 2007: part II: unsettled issues. Circulation 116 (2007) 961-968
3. Airoldi F., Colombo A., Morici N., et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 116 (2007) 745-754
4. Iakovou I., Schmidt T., Bonizzoni E., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005) 2126-2130 [see comment]
5. Ong A.T., McFadden E.P., Regar E., et al. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 45 (2005) 2088-2092
6. Grines C.L., Bonow R.O., Casey Jr. D.E., et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 115 (2007) 813-818
7. Love M.P., Schampaert E., Cohen E.A., et al. The Canadian Association of Interventional Cardiology and the Canadian Cardiovascular Society joint statement on drug-eluting stents. Can J Cardiol 23 (2007) 121-123
8. Ho P.M., Fihn S.D., Wang L., et al. Clopidogrel and long-term outcomes after stent implantation for acute coronary syndrome. Am Heart J 154 (2007) 846-851
9. Spertus J.A., Kettelkamp R., Vance C., et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 113 (2006) 2803-2809
10. Jackevicius C.A., Li P., and Tu J.V. Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation 117 (2008) 1028-1036
11. Jackevicius C.A., Mamdani M., and Tu J.V. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 288 (2002) 462-467
12. Steiner J.F., and Prochazka A.V. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 50 (1997) 105-116
13. Eisenstein E.L., Anstrom K.J., Kong D.F., et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 297 (2007) 159-168
14. Ho P.M., Peterson E.D., Wang L., et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 299 (2008) 532-539
15. Ko D.T., Chiu M., Austin P.C., et al. Safety and effectiveness of drug-eluting stents among diabetic patients: a propensity analysis. Am Heart J 156 (2008) 125-134
16. Tu J.V., Bowen J., Chiu M., et al. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med 357 (2007) 1393-1402
17. Rasmussen J.N., Chong A., and Alter D.A. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 297 (2007) 177-186
18. Vermeire E., Hearnshaw H., Van Royen P., et al. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther 26 (2001) 331-342
19. Avorn J., Monette J., Lacour A., et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 279 (1998) 1458-1462
20. Tseng C.W., Brook R.H., Keeler E., et al. Cost-lowering strategies used by medicare beneficiaries who exceed drug benefit caps and have a gap in drug coverage. JAMA 292 (2004) 952-960
21. Berkowitz S.A., Gerstenblith G., and Anderson G.F. Medicare prescription drug coverage gap: navigating the "doughnut hole" with patients. JAMA 297 (2007) 868-870
22. Schneeweiss S., Patrick A.R., Maclure M., et al. Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: a population-based natural experiment. Circulation 115 (2007) 2128-2135
23. Goldman D.P., Joyce G.F., and Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA 298 (2007) 61-69
24. Benner J.S., Glynn R.J., Mogun H., et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 288 (2002) 455-461